Methyl 3-(4-(2-((2-chloro-4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)(ethyl)amino)-2-phenylethoxy)phenyl)propanoate | 913619-61-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: Methyl 3-(4-(2-((2-chloro-4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)(ethyl)amino)-2-phenylethoxy)phenyl)propanoate
• 英文别名: methyl 3-[4-[2-[2-chloro-N-ethyl-4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)anilino]-2-phenylethoxy]phenyl]propanoate
• CAS: 913619-61-1
• 化学式: C₂₉H₂₈ClF₆NO₄
• 分子量: 603.989
• InChiKey: UUUSQFKWCMPEFI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.5
• 重原子数：
  41
• 可旋转键数：
  12
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.34
• 拓扑面积：
  59
• 氢给体数：
  1
• 氢受体数：
  11

反应信息

• 作为反应物：
  描述：

  Methyl 3-(4-(2-((2-chloro-4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)(ethyl)amino)-2-phenylethoxy)phenyl)propanoate 在 lithium hydroxide 作用下， 以 四氢呋喃 、 水 为溶剂， 生成 3-(4-(2-((2-Chloro-4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)(ethyl)amino)-2-phenylethoxy)phenyl)propanoic acid
  参考文献：
  名称：

  Synthesis and evaluation of anilinohexafluoroisopropanols as activators/modulators of LXRα and β

  摘要：

  A series of branched and unbranched anilinohexafluoroisopropanols related to the known sulfonamide T0901317 were prepared and evaluated as activators/modulators of both LXR alpha and LXR beta. A structure-activity relationship was established and compounds with high potency on both the receptors were identified. Many compounds showed a tendency toward selectivity for LXR beta versus LXR alpha. Several analogues were evaluated for effects on plasma lipoprotein levels in mice. A few of these significantly raised HDL-cholesterol levels in plasma but showed markedly different effects on liver triglyceride content, suggesting that this series may yield candidates with improved efficacy/safety profiles compared to existing molecules. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.06.081
• 作为产物：
  描述：

  2-(4-氨基苯)-1,1,1,3,3,3-六氟-2-丙醇 在 吡啶 、 N-氯代丁二酰亚胺 、 硼烷四氢呋喃络合物 、 偶氮二甲酸二异丙酯 、 Li₂ClO₄ 、 四丁基氟化铵 、 1,8-二氮杂双环[5.4.0]十一碳-7-烯 、 三苯基膦 作用下， 以 丙醇 、 N,N-二甲基甲酰胺 为溶剂， 生成 Methyl 3-(4-(2-((2-chloro-4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)(ethyl)amino)-2-phenylethoxy)phenyl)propanoate
  参考文献：
  名称：

  Synthesis and evaluation of anilinohexafluoroisopropanols as activators/modulators of LXRα and β

  摘要：

  A series of branched and unbranched anilinohexafluoroisopropanols related to the known sulfonamide T0901317 were prepared and evaluated as activators/modulators of both LXR alpha and LXR beta. A structure-activity relationship was established and compounds with high potency on both the receptors were identified. Many compounds showed a tendency toward selectivity for LXR beta versus LXR alpha. Several analogues were evaluated for effects on plasma lipoprotein levels in mice. A few of these significantly raised HDL-cholesterol levels in plasma but showed markedly different effects on liver triglyceride content, suggesting that this series may yield candidates with improved efficacy/safety profiles compared to existing molecules. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.06.081

文献信息

• Synthesis and evaluation of anilinohexafluoroisopropanols as activators/modulators of LXRα and β
  作者：Narendra Panday、Jörg Benz、Denise Blum-Kaelin、Vanessa Bourgeaux、Henrietta Dehmlow、Peter Hartman、Bernd Kuhn、Hassen Ratni、Xavier Warot、Matthew B. Wright

  DOI：10.1016/j.bmcl.2006.06.081

  日期：2006.10

  A series of branched and unbranched anilinohexafluoroisopropanols related to the known sulfonamide T0901317 were prepared and evaluated as activators/modulators of both LXR alpha and LXR beta. A structure-activity relationship was established and compounds with high potency on both the receptors were identified. Many compounds showed a tendency toward selectivity for LXR beta versus LXR alpha. Several analogues were evaluated for effects on plasma lipoprotein levels in mice. A few of these significantly raised HDL-cholesterol levels in plasma but showed markedly different effects on liver triglyceride content, suggesting that this series may yield candidates with improved efficacy/safety profiles compared to existing molecules. (c) 2006 Elsevier Ltd. All rights reserved.